...

首页> 外文期刊>European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR) >Preclinical evaluation of OTX015, a novel BET-BRD inhibitor, on small cell lung cancer (SCLC) cell lines

【24h】

Preclinical evaluation of OTX015, a novel BET-BRD inhibitor, on small cell lung cancer (SCLC) cell lines

机译：新型BET-BRD抑制剂OTX015对小细胞肺癌（SCLC）细胞系的临床前评估

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

团队文献服务 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR) 》 |2014年第6期| 共1页
作者
Ijaz N.; Astorgues-Xerri L.; Odore E.; Bekradda M.; Cvitkovic E.; Noel K.; Raymond E.; Riveiro M.;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学 ;
关键词

相似文献

外文文献
中文文献
专利

1. Preclinical evaluation of OTX015, a novel BET-BRD inhibitor, on small cell lung cancer (SCLC) cell lines [J] . Ijaz N., Astorgues-Xerri L., Odore E., European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR) . 2014 ,第Suppla6期

机译：新型BET-BRD抑制剂OTX015对小细胞肺癌（SCLC）细胞系的临床前评估
2. OTX015, a BET-bromodomain (BET-BRD) inhibitor, potentiates the in vitro effects of chemotherapy drugs and targeted agents in human leukemic cell lines [J] . Astorgues-Xerri L., Canet-Jourdan C., Bekradda M., European journal of cancer: official journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR) . 2014 ,第Suppla6期

机译：OTX015是BET溴结构域（BET-BRD）抑制剂，可增强化学疗法药物和靶向药物在人类白血病细胞系中的体外作用
3. 288 POSTER The selective Aurora B kinase inhibitor AZD1152 inhibits in vitro growth in small cell lung cancer (SCLC) cell lines [J] . B.Helfrich, M.Garcia, J.Haney, European Journal of Cancer Supplements . 2008 ,第12期

机译：288 POSTER选择性Aurora B激酶抑制剂AZD1152抑制小细胞肺癌（SCLC）细胞系的体外生长
4. DEVELOPMENT OF A LIPOSOMAL DRUG CARRIER TO DELIVER SUFFICIENT ANTI-CANCER DRUG INTO MULTI DRUG RESISTANT (MDR)-SMALL CELL LUNG CANCER (SCLC) [C] . T. Kobavashi, Y. Okada, T. Ishida, International symposium on controlled release of bioactive materials;Consumer diversified products conference . 2001

机译：脂质体药物载体的开发，以将有效的抗癌药物输送到抗多药（MDR）-小细胞肺癌（SCLC）中
5. Gene expression analysis of human non -small cell lung cancer subtypes, adenocarcinoma and squamous cell carcinoma, and mouse lung epithelial cell lines: Implications in lung tumorigenesis [D] . Silvers, Amy Lynn. 2002

机译：人类非小细胞肺癌亚型，腺癌和鳞状细胞癌以及小鼠肺上皮细胞系的基因表达分析：在肺肿瘤发生中的意义
6. P25. In vitro evaluation of the anticancer activity of ganetespib in combination with standard chemotherapeutics in small cell lung cancer (SCLC) cell lines [O] . Gerhard Hamilton, Barbara Rath, Elisabeth Maritschnegg, 2014

机译：P25。 ganetespib与标准化学疗法联合在小细胞肺癌（SCLC）细胞系中的体外抗癌活性评估
7. Synergistic Anticancer Activity of Topotecan— Cyclin-Dependent Kinase Inhibitor Combinations against Drug-Resistant Small Cell Lung Cancer (SCLC) Cell Lines [O] . Gerhard Hamilton, Ulrike Olszewski, Lukas Klameth, Ernst Ulsperger, 2013

机译：拓扑替康—细胞周期蛋白依赖性激酶抑制剂组合对耐药小细胞肺癌（SCLC）细胞系的协同抗癌活性

获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

客服微信
服务号